Predictive biomarker for cancer therapy

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a predictive biomarker method for identifying whether patients with cancer or autoimmune diseases will respond to therapies involving TLR-9 agonists, specifically by measuring the frequency of activated natural killer T (NKT) cells in a patient's blood. The invention also includes specific DNA constructs (TLR-9 agonists) for treatment and a kit for predicting patient response, thereby enabling more effective and personalized therapy.

Use CasesContent extracted from patent full text and abstract with AI.

• Personalized cancer treatment selection, allowing physicians to identify patients most likely to benefit from TLR-9 agonist immunotherapy.
• Monitoring response to TLR-9 immunotherapy in real-time during cancer or autoimmune disease treatment.
• Screening patients prior to initiating TLR-9 agonist therapy for eligibility, improving clinical trial design and outcomes.
• Incorporating the biomarker assay into pharmaceutical kits alongside TLR-9 agonist drugs for commercial application.
• Enabling development of companion diagnostics for new immunotherapy drugs targeting TLR-9 or similar immune pathways.

BenefitsContent extracted from patent full text and abstract with AI.

• Improves effectiveness and safety of cancer therapy by identifying patients likely to respond to TLR-9 agonist treatment, thus avoiding unnecessary treatment and side effects in non-responders.
• Supports more personalized and individualized medicine by tailoring therapy to a patient's immune status.
• Facilitates earlier and more accurate prediction of therapeutic outcomes, improving overall patient management.
• May reduce drug costs and healthcare expenses by enabling more targeted use of expensive immunotherapies.
• Can be integrated into pharmaceutical products and diagnostic kits, streamlining the clinical workflow.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

A method for predicting or monitoring whether a patient suffering from cancer or an auto immune disease will respond to treatment with a TLR-9 (toll-like recptor 9) agonist by determining the frequency of activated natural killer T (NKT) cells. The agonist may be a DNA construct comprising a sequence motif N1N2CGN3N4, wherin N1N2 and N3N4 is any combination of A, C, G and T. Also claimed is the use of a TLR-9 agonist to treat cancer.